These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 16009830)

  • 1. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
    Suhler EB; Smith JR; Wertheim MS; Lauer AK; Kurz DE; Pickard TD; Rosenbaum JT
    Arch Ophthalmol; 2005 Jul; 123(7):903-12. PubMed ID: 16009830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial.
    Suhler EB; Lowder CY; Goldstein DA; Giles T; Lauer AK; Kurz PA; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Tessler HH; Smith JR; Rosenbaum JT
    Br J Ophthalmol; 2013 Apr; 97(4):481-6. PubMed ID: 23376607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab in the treatment of refractory posterior uveitis.
    Joseph A; Raj D; Dua HS; Powell PT; Lanyon PC; Powell RJ
    Ophthalmology; 2003 Jul; 110(7):1449-53. PubMed ID: 12867408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab therapy for refractory uveitis: a pilot study.
    Diaz-Llopis M; García-Delpech S; Salom D; Udaondo P; Hernández-Garfella M; Bosch-Morell F; Quijada A; Romero FJ
    J Ocul Pharmacol Ther; 2008 Jun; 24(3):351-61. PubMed ID: 18476805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective case review of pediatric patients with uveitis treated with infliximab.
    Rajaraman RT; Kimura Y; Li S; Haines K; Chu DS
    Ophthalmology; 2006 Feb; 113(2):308-14. PubMed ID: 16406545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease.
    Abu El-Asrar AM; Abboud EB; Aldibhi H; Al-Arfaj A
    Int Ophthalmol; 2005 Jun; 26(3):83-92. PubMed ID: 17031510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab.
    Al Rashidi S; Al Fawaz A; Kangave D; Abu El-Asrar AM
    Ocul Immunol Inflamm; 2013 Dec; 21(6):468-74. PubMed ID: 23734940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.
    Nussenblatt RB; Peterson JS; Foster CS; Rao NA; See RF; Letko E; Buggage RR
    Ophthalmology; 2005 May; 112(5):764-70. PubMed ID: 15878055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).
    Benitez-del-Castillo JM; Martinez-de-la-Casa JM; Pato-Cour E; Méndez-Fernández R; López-Abad C; Matilla M; Garcia-Sanchez J
    Eye (Lond); 2005 Aug; 19(8):841-5. PubMed ID: 15389273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
    Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
    Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating intraocular inflammatory disease in the 21st century.
    Nussenblatt R
    Arch Ophthalmol; 2005 Jul; 123(7):1000-1. PubMed ID: 16009844
    [No Abstract]   [Full Text] [Related]  

  • 13. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis.
    Murphy CC; Ayliffe WH; Booth A; Makanjuola D; Andrews PA; Jayne D
    Ophthalmology; 2004 Feb; 111(2):352-6. PubMed ID: 15019389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
    Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
    Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis.
    Simonini G; Zannin ME; Caputo R; Falcini F; de Martino M; Zulian F; Cimaz R
    Rheumatology (Oxford); 2008 Oct; 47(10):1510-4. PubMed ID: 18676502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab therapy for the treatment of refractory ocular inflammatory disease.
    Sobrin L; Kim EC; Christen W; Papadaki T; Letko E; Foster CS
    Arch Ophthalmol; 2007 Jul; 125(7):895-900. PubMed ID: 17620567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
    Galor A; Perez VL; Hammel JP; Lowder CY
    Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable response to high-dose infliximab for refractory childhood uveitis.
    Kahn P; Weiss M; Imundo LF; Levy DM
    Ophthalmology; 2006 May; 113(5):860-4.e2. PubMed ID: 16545455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.
    Nussenblatt RB; Thompson DJ; Li Z; Chan CC; Peterson JS; Robinson RR; Shames RS; Nagarajan S; Tang MT; Mailman M; Velez G; Roy C; Levy-Clarke GA; Suhler EB; Djalilian A; Sen HN; Al-Khatib S; Ursea R; Srivastava S; Bamji A; Mellow S; Sran P; Waldmann TA; Buggage RR
    J Autoimmun; 2003 Nov; 21(3):283-93. PubMed ID: 14599854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.
    Gerloni V; Pontikaki I; Gattinara M; Desiati F; Lupi E; Lurati A; Salmaso A; Fantini F
    Arthritis Rheum; 2005 Feb; 52(2):548-53. PubMed ID: 15693004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.